Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 1/20 | 0.48 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.47 |
| ▸ | SELE | P16581 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | LIPE | Q05469 | 7/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21628409 | 0.91 | HPGD (0.44) | RAF1ICAM1SELESMN1; SMN2HPGD | |
| SCHEMBL21628391 | 0.91 | HPGD (0.44) | RAF1ICAM1SELESMN1; SMN2HPGD | |
| SCHEMBL21628439 | 0.90 | SMN1; SMN2 (0.47) | RAF1ICAM1SELESMN1; SMN2HPGD | |
| SCHEMBL21628896 | 0.89 | HDAC1 (0.49) | SMN1; SMN2LIPE | |
| SCHEMBL21628547 | 0.89 | HPGD (0.43) | RAF1ICAM1SELESMN1; SMN2HPGD | |
| SCHEMBL21628534 | 0.88 | SMN1; SMN2 (0.42) | RAF1ICAM1SELESMN1; SMN2HPGD | |
| SCHEMBL21628650 | 0.86 | LMNA (0.57) | SMN1; SMN2LIPELMNAPTGER4KDM4E | |
| SCHEMBL21628614 | 0.86 | NPC1 (0.45) | RAF1SMN1; SMN2HPGDTSHRHTT | |
| SCHEMBL21628745 | 0.86 | MMP13 (0.56) | SMN1; SMN2HPGDTSHRHTTPTGER4 | |
| SCHEMBL21628645 | 0.85 | SMN1; SMN2 (0.47) | SMN1; SMN2LIPELMNASCN9APTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230406814-A2 | NOVEL AROMATIC COMPOUNDS | Xeniopro GmbH (DE) | 2023-12-21 | — | — | US | disclosed |
| US-11591289-B2 | Aromatic compounds | Xeniopro GmbH (DE) | 2023-02-28 | — | — | US | disclosed |
| US-11591289-B2 | Aromatic compounds | Xeniopro GmbH (DE) | 2023-02-28 | — | — | US | disclosed |
| US-20220348535-A2 | NOVEL AROMATIC COMPOUNDS | Xeniopro GmbH (DE) | 2022-11-03 | — | — | US | disclosed |
| US-20210107863-A2 | NOVEL AROMATIC COMPOUNDS | Xeniopro GmbH (DE) | 2021-04-15 | — | — | US | disclosed |
| US-20200031763-A1 | NOVEL AROMATIC COMPOUNDS | Xeniopro GmbH (DE) | 2020-01-30 | — | — | US | disclosed |
| US-20200031763-A1 | NOVEL AROMATIC COMPOUNDS | Xeniopro GmbH (DE) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348535-A2 | NOVEL AROMATIC COMPOUNDS | AHR, TYR, MUSK | RAF1 2759/4885ICAM1 1962/4885SELE 2216/4885 |
| US-11591289-B2 | Aromatic compounds | AHR, TYR, MUSK | RAF1 2711/4885ICAM1 1848/4885SELE 2237/4885 |
| US-20210107863-A2 | NOVEL AROMATIC COMPOUNDS | AHR, TYR, MUSK | RAF1 2759/4885ICAM1 1962/4885SELE 2216/4885 |
| US-20230406814-A2 | NOVEL AROMATIC COMPOUNDS | AHR, TYR, MUSK | RAF1 2759/4885ICAM1 1962/4885SELE 2216/4885 |
| US-20200031763-A1 | NOVEL AROMATIC COMPOUNDS | AHR, TYR, MUSK | RAF1 2759/4885ICAM1 1962/4885SELE 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.